Apotex Health lifted its fiscal 2027 revenue-growth forecast to 9%–10% from 7%–8% after new drug launches and stronger sales helped drive first-half performance. The Canadian pharmaceutical company also raised its expected adjusted EBITDA margin to 31%, from 30%.
The revised outlook accompanied results for the three months ended Sept. 30. Net income rose to C$100.8 million ($70.7 million) from C$82.9 million a year earlier, while earnings per share slipped to C$0.41 from C$0.43. Apotex attributed the per-share decline to a higher share count following its recent initial public offering.
Adjusted earnings, excluding revenue from the company’s U.S. generic version of the blood cancer drug Revlimid, were C$0.57 a share. Analysts surveyed by FactSet had expected C$0.37.
Revenue increased 1.1% to C$852.9 million. Excluding Revlimid sales recorded in the prior-year period, revenue rose 4.9%, ahead of the C$828.3 million consensus estimate. Canadian sales climbed nearly 15%; branded and biosimilar sales rose 18%, and conventional generics increased 11%.
Apotex said its stronger outlook reflects a solid first-half operating performance, supported by new drug launches and accelerating revenue growth.
Comments (0)
No comments yet. Be the first!